18F-PEG6-IPQA

18F-PEG6-IPQA is a novel small molecule radiotracer developed by the MD Anderson Cancer Center for positron emission tomography (PET) imaging. It is designed to specifically target and irreversibly bind to the active mutant form of the epidermal growth factor receptor (EGFR) kinase, particularly the L858R mutation commonly found in non-small cell lung cancer (NSCLC). By visualizing EGFR expression and activity, this imaging agent aims to assist in the selection of patients for individualized therapy with EGFR tyrosine kinase inhibitors (TKIs) and to monitor treatment response. It is currently being evaluated in Phase I clinical trials for patients with Stage IV EGFR-mutant NSCLC.

Other names

[18F]F-PEG6-IPQA4-[(3-iodophenyl)amino]-7-(2-[2-{2-(2-[2-{2-((18)F-fluoroethoxy)-ethoxy}-ethoxy]-ethoxy)-ethoxy}-ethoxy]-quinazoline-6-yl-acrylamide)